The dynamics of the main epidemiological indicators among living in Moscow patients with diabetes mellitus (2013–2018)

BACKGROUND: State Register of Diabetes Mellitus (SRDM) plays an important role in the dynamic analysis of the epidemiological parameters that evaluate the disease itself and its complications, and also helps to analyze the quality of specialized medical care for patients. To solve modern scientific and practical problems, it is important to analyze data not only among the entire population of Russia, but also in large administrative-territorial subjects of the country. AIMS: To Study the dynamics of the main epidemiological indicators (values) among patients with type 1 diabetes mellitus (DM1) and type 2 diabetes mellitus (DM2) living in Moscow for the period from 2013 to 2018 according to the State Register of Diabetes Mellitus (SRDM). MATERIALS AND METHODS: The analysis of Moscow region of the SRDM database was conducted. According to it there were registered 345.1 thousand patients with diabetes by 01.01.2019. RESULTS: During the period from 2013 to 2018 the total number of patients with DM increased up 9.8% (from 314.4 thousand to 345.1 thousand people). DM2 accounts for 94% of the total number of patients. According to SRDM the prevalence of DM1 on 100 thousand population has grown up 6.9% (from 152.2 in 2013 to 162.7 in 2018); DM2 by 9.6% (from 2864.7 in 2013 to 3139.4 in 2018). The incidence of DM1 per 100 thousand people decreased down to 6.4% (from 4.7 in 2013 to 4.4% in 2018); DM2 grew up 4.3% (from 198.1 in 2002, to 206.6 in 2018). Throughout the study period the incidence of DM2 was higher among women, while the opposite trend was observed among women with DM1. The mortality among people with DM1 in 2018 was 1.6 per 100 thousand among adult population (in 2017 it was 1.7); among patients with DM2 the mortality was 56.6 people per 100 thousand among adult population (in 2017 it was 65.6). The first place among the direct causes of death among patients with DM1 and DM2 in 2018 was occupied by cardiovascular diseases (57.5% and 67.9%, respectively), the second place oncological diseases (9.9% and 12.2%). CONCLUSIONS: The results of the epidemiological analysis showed that since 2013 in Moscow there has been an increase in the prevalence of diabetes, against the background of stable indicators of incidence (except for the organizational period of adapting to the new online data entry system of SRDM). The leading causes of death of patients with diabetes are cardiovascular and oncological diseases.

Pengujian Black Box pada Aplikasi Pertokoan Minimarket Menggunakan Metode Equivalence Partitioning

Quality measurements in software are currently required before the software will be used by users. This aims to determine the weakness of the system so that the data generated can match the data entered after the data is executed. This method focuses on data entry, system display, memory usage, and data execution speed so that if the input data does not match what is expected then the system fails.In implementation problems often arise when testers are never sure whether the software being tested has actually passed the test. This happens because there may be several execution paths that have never been tested. The minimarket stock management application will be tested using a black box test where this test is only intended to see if the program matches the function desired by the program without knowing the program code used. To generate test case designs automatically in black box method software testing with the equality.technique partition technique.

Diabetes Registry of Pakistan

Diabetes registries can be used to monitor the prevalence and incidence of diabetes. Diabetes registries are used in many countries for population management of diabetes, outcomes management, and development of Clinician finding Support Structure, for example, National Diabetes Registry (NDR) in Sweden and Singapore diabetes registry. According to 2nd National Diabetes Survey of Pakistan (NDSP) 2016-2017, overall 26.3% adult (≥20) suffer from diabetes (27.4 million people). Health Research Advisory Board (HRAB) of Pakistan has initiated the mission of developing disease registries countrywide. Diabetes Registry of Pakistan (DROP) under the supervision of Prof. Abdul Basit and Dr. Asher Fawwad to enumerate the degree of the national disease burden. For type 1 diabetes, Diabetes Registry of Pakistan for type 1 (DROP-1) has already started. DROP-1 can be a good pilot arm for developing the robust methodology for DROP. The upcoming and the ongoing research is periodically being linked with the registry to ensure its modernization. This registry is a useful tool for tracking the status of patient, in order to limit the burden of data collection. A web-based data entry system and automated random sampling has enabled useful data collection and tracking with relatively minimal effort. doi: https://doi.org/10.12669/pjms.36.3.1877 How to cite this:Basit A, Fawwad A, Baqa K. Diabetes Registry of Pakistan. Pak J Med Sci. 2020;36(3):---------. doi: https://doi.org/10.12669/pjms.36.3.1877 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The establishment of metadatabase: The program Euromarsin for the marin sediments samples

The project EUMARSIN (European MARine Sediment Information Network), is an international scientific project financed by the European Community and its aim has been the development of an internet retrievable metadatabase containing the marine sediment samples collected from the European Seas. The project, with duration of two years, started on November 1998 and ended on October 2000. This paper elucidates the concerted activities of the partners participating in the project and represent the Marine Geology Departments of the Eurogeosurveys (ERG) now called Geological Survey Organizations (GSOs) of the European Union maritime countries, with the additional participation of a private company specialized on marine data management. The metadata can be accessed on the EU-SEASED Website through both an alphanumeric search and retrieval interface and by a geographical interface which allows the user to define an area of interest on a scrollable map showing the distribution of the seafloor sample/core locations. The EUMARSIN metadatabase now contains approximately 180.000 seabed samples collected by the Geological Surveys and other research organizations, universities, hydrographie offices and commercial companies in Europe. The metadatabase will be regularly updated by the partners on an on-line data entry system which will allow other organizations to contribute their metadata either retrospectively or as new data. The outcome of the EUMARSIN project, will be the successful establishment of the http://www.eu-seased.net marine sediment metadatabase and the development of analogous databases in each Geological Institute with the same specifications. This constitutes the first pan-European metadatabase in the marine geoscience field.

Use of Palivizumab in Germany – Report from the German Synagis™ Registry 2009 – 2016

Background Following national recommendations, palivizumab is administered in Germany to high-risk infants to prevent hospitalizations related to Respiratory Syncytial Virus infection. Methods In this post marketing observational study (German SYNAGIS™ Registry) data on risk factors and the clinical course of children, who received at least one palivizumab injection between 2009–2016 (01 September to June 30) were entered into an internet-based data entry system by the attending physicians after informed consent. Results 63 572 immunizations were documented for 12 729 evaluable patients (EVP) from 2009 to 2016, with an average of 5.0 immunizations per patient per season. 45% of infants received more than 5 injections. The predominant primary reason for immunization was premature birth (74%). In the EVP the rate of hospitalizations with causal relationship to RSV was 0.7% (=92/12 729) or 1.2% in a worst case scenario including patients with missing RSV test. In patients with hemodynamically significant congenital heart disease as main indication, RSV-related hospitalization rate was 0.8%. Intensive care was necessary in 16.9% (median duration 3 days), mechanical ventilation in 8.0%. No death related to RSV infection was reported. Conclusion Keeping in mind the limitations of an uncontrolled prospective observational study, our results confirm the effectiveness and safety of palivizumab prophylaxis. The total number of patients with hsCHD is lower than expected. A better adjustment to the regional epidemiology would probably reduce the need for more than 5 injections.